Preventing nausea and vomiting from T-DXd in breast cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is looking at whether a specific medication can help prevent or reduce nausea and vomiting caused by the breast cancer drug T-DXd (trastuzumab deruxtecan). If you are starting T-DXd for the first time, this study might help you manage those side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must have a confirmed diagnosis of breast cancer
- You must be about to receive your first full dose of the anti-cancer drug T-DXd (trastuzumab deruxtecan)
- You must be able to take care of yourself and be up and about (a score of 2 or lower on the ECOG scale)
- You must agree to follow the study rules and give written consent
- You cannot be taking certain other medications that might affect nausea or vomiting (like other anti-nausea drugs, opioids, or psychiatric drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
This trial tests whether a steroid called dexamethasone, given before T-DXd, can reduce the risk of a rare but serious lung side effect (interstitial lung disease) in people with advanced breast cancer. If it works, it may make treatment safer.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
Hear when a new Breast Cancer Patients Treated With T-DXd trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.